World’s first biosimilar antibody* is approved in Korea

July 23, 2012 6:41 AM

South Korean biosimilar manufacturer Celltrion, today declared that, Korean Food and Drug Administration approved its first biosimilar monoclonal antibody, Remsima.

Remsima is a biosimilar version of Remicade, the blockbuster in Rheumatoid Arthitis (RA). Korean FDA approved the product in several indications including RA, ankylosing spondylitis, ulcerative colitis, psoriasis and Crohn’s disease.

Celltrion already made an application for Remsima in the EU and according to Celltrion press release, the product will be launched in many countries in Asia, South America by the end of this year.

Remsima’s clinical results were announced in the latest European League Against Rheumatism (EULAR) congress in Berlin, Germany.


*: As Korean regulations are inline with global biosimilar guidelines, Remsima can be considered as “world’s first biosimilar antibody”. Back in 2007, Reditux was approved in India as a biosimilar version of Mabthera but India’s guidelines were not inline with the globally accepted biosimilar development rules and although the product is still on the market in some countries, it is not launched worldwide, yet.


Source: Celltrion press release

Comments are closed

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!